ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2237

Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies

Isabela Bertoglio1, Glaucia Abrahão 2, Michelle Remião Ugolini-Lopes 3, Fernando Henrique Souza 4, Renata Miossi 4, Samuel Shinjo 5 and Eloisa Bonfa 6, 1Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo (HCFMUSP), Sao Paulo, Brazil, 2Hospital das Clinicas da Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil, 3Rheumatology Division - Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo (FMUSP), Sao Paulo, Sao Paulo, Brazil, 4Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 5Univeristy Of Sao Paulo, São Paulo, Brazil, 6Rheumatology Division, Hospital das Clinicas, Faculdade de Medicina da Universidade de Sao Paulo (HCFMUSP), Sao Paulo, Brazil., Sao Paulo, Sao Paulo, Brazil

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: outcomes and myopathy

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 12, 2019

Title: Patient Outcomes, Preferences, & Attitudes Poster II: Patient Preferences, Beliefs, & Experiences

Session Type: Poster Session (Tuesday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Treat-to-target (T2T) strategy has become the best approach to treat several rheumatic disorders. However, most targets are only based on specialists’ opinions, which may not reflect exactly the main patients’ concerns during treatment. There is evidence that switching to a more patient-centered healthcare system seems to enhance treatment adherence and improve outcomes. Therefore, the purposes of this research were: a) to assess the concerns of the patients with systemic autoimmune myopathies (SAMs) during follow-up and compare to the rheumatologists’ concerns; b) to gather patients’ and physicians’ concerns to develop a SAMs outcome standard set.

Methods: From 2018 to 2019, total of the 93 consecutive adult patients with SAMs (49 dermatomyositis and 11 polymyositis – EULAR/ACR 2017, and 33 anti-synthetase syndrome – Connors et al., 2010) and 51 rheumatologists from a tertiary center were invited to answer a standardized questionnaire. Initially, an open questionnaire was applied in order to assess unbiased concerns of both groups. Thereby, the top 10 answers were selected and applied a multiple-choice questionnaire, inquiring the top 3 major concerns. Answers of each group were plotted into charts and frequencies were compared. The agreement rate was calculated by the sum of lowest frequency of each concern. Concerns were gathered in a SAMs outcome standard set, following the methodology proposed by the International Consortium for Health Outcomes Measurement (ICHOM). We also evaluated if the patients’ concerns were associated with any current clinical features, previous manifestations or comorbidities.

Results: The top three concerns raised among the patients were: to avoid side effect of medication (51%), to improve muscle weakness (49%) and to prevent loss of functionality (35%). The top three concerns among rheumatologists were: prevent loss of functionality (71%), ensure quality of life (63%) and achieve disease remission (63%). The agreement rate between both groups was 41%.The patients’ concerns that rheumatologists did not mention were respectively the improvement of: muscle pain (33% vs. 0%, P=0.001), diffuse pain (25% vs. 0%, P=0.001), skin lesions (23% vs. 0%, P=0.001) and fatigue (18% vs. 0%, P=0.001) – all symptoms related worries. The rheumatologists’ concerns that patients did not mention were respectively the: achievement of disease remission (63% vs. 0%, P=0.001) and prednisone dose (0% vs. 22%, P=0.001). The concerns of pain and fatigue were not associated with other diagnosis such as fibromyalgia or depression/anxiety. Gathering both point of view, we developed a SAMs outcome standard set (Figure 1). 

Conclusion: Even though functionality and muscle weakness are still major concerns for physicians and patients, there are additional patients’ concerns that should be assessed routinely during SAMs treatment and follow-up. Patients consider that controlling pain and fatigue are important outcomes to be pursued in SAMs and rheumatologists should be aware of these to provide a better assistance and ensure treatment adherence.


Disclosure: I. Bertoglio, None; G. Abrahão, None; M. Remião Ugolini-Lopes, None; F. Souza, None; R. Miossi, None; S. Shinjo, None; E. Bonfa, Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq #305068/2014-8), 2, Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP #2015/03756-4 and #2010/10749-0), 2.

To cite this abstract in AMA style:

Bertoglio I, Abrahão G, Remião Ugolini-Lopes M, Souza F, Miossi R, Shinjo S, Bonfa E. Gathering Patients’ and Physicians’ Perceptions to Improve Outcomes in Systemic Autoimmune Myopathies [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/gathering-patients-and-physicians-perceptions-to-improve-outcomes-in-systemic-autoimmune-myopathies/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/gathering-patients-and-physicians-perceptions-to-improve-outcomes-in-systemic-autoimmune-myopathies/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology